Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma

Claim 2

A composition for inhibiting the influx of leukocytes into the lung and other organs during sepsis or other infectious or non-infectious trauma; and/or for treating inflammation in the lung and other organs in patients having an inflammation caused by sepsis or other infectious or non-infectious trauma; and/or eliminating or reducing inflammation in a patient wherein the patient is being administered an anti-infective agent; and/or for assisting in the administration of a therapeutic drug to a patient during chemotherapy; which comprises an effective amount of an anti-CD18 antibody or active fragment thereof.

Claim 3

The composition of Claim 1 wherein the anti-CD18 antibody is anti-CD18 mAb IB4.

Claim 4

The composition of Claim 1 wherein the anti-CD18 antibody is anti-CD18 mAb 60.3.

Claim 5

The composition of Claim 1 wherein said composition is prepared in suitable form for intravenous administration.

Claim 6

The composition of Claim 1 wherein said antibody is present in an amount effective to treat an infection.

Claim 7

The composition of Claim 1 wherein said antibody is present in an amount effective to treat a non-infectious trauma.

Claim 8

The composition of Claim 1 wherein said antibody is present in an amount effective to treat endotoxic shock.

Claim 9

The composition of Claim 1 wherein said antibody is present in an amount effective to treat adult respiratory distress syndrome.

Claim 10

The composition of Claim 5 wherein the infection is associated with a disease state selected from the group consisting of meningitis, encephalitis, arthritis, uveitis, colitis, inflammatory bowel/Crohn's disease, dermatitis, psoriasis, and adult respiratory distress syndrome.

Claim 11

The composition of Claim 1 wherein said antibody is present in an amount effective to treat an immune disorder selected from the group consisting of acute hypersensitivity, delayed hypersensitivity, graft vs. host disease, pernicious anemia, diabetes mellitus, flares during rheumatoid arthritis, diseases that involve leukocyte diapedesis, antigen-antibody complex mediated diseases, and transplant rejection.

Claim 12

The composition of Claim 1 wherein said antibody is present in an amount effective to treat an iatrogenic state.

Claim 13

The composition of Claim 1 wherein the anti-­infective agent is a beta-lactam antibiotic.

Claim 14

Use of an anti-CD18 antibody or active fragment thereof, for the manufacture of a composition useful for inhibiting the influx of leukocytes into the lung and other organs during sepsis or other infectious or non-­infectious trauma and/or to treat inflammation in the lung and other organs in patients having an inflammation caused by sepsis or other infectious or non-infectious trauma, and/or treating inflammation in the lung and other organs in patients having an inflammation caused by sepsis or other infectious or non-infectious trauma; and/or eliminating or reducing inflammation in a patient wherein the patient is being administered an anti-­infective agent; and/or for assisting in the administration of a therapeutic drug to a patient during chemotherapy.

Claim 15

Use of an anti-CD18 antibody or active fragment thereof, for the manufacture of a composition useful for inhibiting the influx of leukocytes into the lung and other organs during sepsis or other infectious or non-­infectious trauma and/or to treat inflammation in the lung and other organs in patients having an inflammation caused by sepsis or other infectious or non-infectious trauma, and/or treating inflammation in the lung and other organs in patients having an inflammation caused by sepsis or other infectious or non-infectious trauma; and/or eliminating or reducing inflammation in a patient wherein the patient is being administered an anti-­infective agent; and/or for assisting in the administration of a therapeutic drug to a patient during chemotherapy.

Claim 16

Use of Claim 13 wherein the anti-CD18 antibody is anti-CD18 mAb IB4.

Claim 17

Use of Claim 13 wherein the anti-CD18 antibody is anti-CD18 mAb 60.3.

Claim 18

Use of Claim 13 wherein the monoclonal antibody or fragment thereof is administered intravenously.

Claim 19

Use of Claim 13 wherein the influx of leukocytes results from endotoxic shock, and/or adult respiratory distress syndrome.

Claim 20

Use of Claim 13 wherein said influx of leukocytes and/or said inflammation results from infection and the infection is associated with a disease state selected from the group consisting of meningitis, encephalitis, arthritis, uveitis, colitis, inflammatory bowel/Crohn's disease, dermatitis, psoriasis, and adult respiratory distress syndrome.

Claim 21

Use of Claim 13 wherein said influx and/or said inflammation results from an immune disorder selected from the group consisting of acute hypersensitivity, delayed hypersensitivity, graft vs. host disease, pernicious anemia, diabetes mellitus, flares during rheumatoid arthritis, diseases that involve leukocyte diapedesis, antigen-antibody complex mediated diseases, and transplant rejection.

Claim 22

Use of Claim 13 wherein the influx of leukocytes results from an iatrogenic state.

Claim 23

Use of Claim 13 wherein said antibody or fragment thereof is administered prior to, concurrent with, or after, the administration of the anti-infective agent.

Claim 24

Use of Claim 21 wherein the anti-infective agent is a beta-lactam antibiotic.

Claim 25

In a diagnostic method including the introduction of a marker material into tissue, the step of causing the iatrogenic opening of the endothelium to prevent leukocyte ingress into said tissue by administering to said endothelium an inhibitory amount of an anti-CD18 antibody or active fragment thereof.

Claim 26

In a diagnostic method including the introduction of a marker material into tissue, the step of causing the iatrogenic opening of the endothelium to prevent leukocyte ingress into said tissue by administering to said endothelium an inhibitory amount of an anti-CD18 antibody or active fragment thereof.

Claim 27

In a diagnostic method including the harvesting of a quantity of leukocytes from a test subject, the step of administering to the endothelium of said test subject prior to the harvesting of said leukocytes of an amount of an anti-CD18 antibody or active fragment thereof, effective to prevent the binding of a sufficient quantity of said leukocytes to provide adequate harvest of said leukocytes for the successful practice of said diagnostic method

Claim 28

In a diagnostic method including the harvesting of a quantity of leukocytes from a test subject, the step of administering to the endothelium of said test subject prior to the harvesting of said leukocytes of an amount of an anti-CD18 antibody or active fragment thereof, effective to prevent the binding of a sufficient quantity of said leukocytes to provide adequate harvest of said leukocytes for the successful practice of said diagnostic method